This is a working overview of REV-ERB, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-24 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Premnaspirodiene oxygenase is a cytochrome P450 protein containing heme, isolated from Hyoscyamus muticus. It uses molecular oxygen for the oxidation, which proceeds in two steps via solavetivol, and requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate.
It is a key feature of NMR that the resonance frequency of nuclei in a particular sample substance is usually directly proportional to the strength of the applied magnetic field. It is this feature that is exploited in imaging techniques; if a sample is placed in a non-uniform magnetic field then the resonance frequencies of the sample's nuclei depend on where in the field they are located. This effect serves as the basis of magnetic resonance imaging. The principle of NMR usually involves three sequential steps:
=== Biosynthesis === Almost all animal tissues synthesize cholesterol from acetyl-CoA. All animal cells (with some exceptions within the invertebrates) manufacture cholesterol, for both membrane structure and other uses, with relative production rates varying by cell type and organ function. About 80% of total daily cholesterol production occurs in the liver and the intestines; other sites of higher synthesis rates include the brain, the adrenal glands, and the reproductive organs. Synthesis within the body starts with the mevalonate pathway where two molecules of acetyl-CoA condense to form acetoacetyl-CoA. This is followed by a second condensation between acetyl-CoA and acetoacetyl-CoA to form 3-hydroxy-3-methylglutaryl CoA (HMG-CoA).
Sources: en.wikipedia.org
== Dietary issues == Leaf protein is a good source of amino acids, with methionine being a limiting factor. It is nutritionally better than seed proteins and comparable to animal proteins (other than those in egg and milk). In terms of digestibility, whole LPC has digestibility in the range 65–90%. The green fraction has a much lower digestibility that may be <50%, while the white fraction has digestibility >90%. The challenges that have to be overcome using lucerne and cassava, two high density monoculture crops, include the high fiber content and other antinutritional factors, such as phytate, cyanide, and tannins. Lablab beans, Moringa oleifera, tree collards and bush clover may also be used. Flavors of different species vary greatly. For testing new leaf species for use as LPCs a non-targeted approach has been developed that uses an ultra-high-resolution hybrid ion trap orbitrap mass spectrometer with electrospray ionization coupled to an ultra-high pressure two-dimensional liquid chromatograph system. An open source software toolchain was also developed for automated non‐targeted screening of toxic compounds for LPCs. The process uses three tools: 1) mass spectrometry analysis with MZmine 2, 2) formula assignment with MFAssignR, and 3) data filtering with ToxAssign. Studies have looked at the potential for deciduous trees and coniferous tree leaves.
== Live performances == The members of Rush shared a strong work ethic, desiring to accurately recreate songs from their albums when playing live performances. To achieve this goal, beginning in the late 1980s, Rush included a capacious rack of digital samplers in their concert equipment to recreate the sounds of non-traditional instruments, accompaniments, vocal harmonies, and other sound "events" in real time to match the sounds on the studio versions of the songs. In live performances, the band members shared duties throughout most songs. Each member had one or more MIDI controllers, which were loaded with different sounds for each song, and they used available limbs to trigger the sounds while simultaneously playing their primary instrument(s). With this technology the group was able to present their arrangements in a live setting with the level of complexity and fidelity fans had come to expect, and without the need to resort to the use of backing tracks or employing an additional band member during their initial run. The members' coordinated use of pedal keyboards and other electronic triggers to "play" sampled instruments and audio events was subtly visible in their live performances, especially on the R30: 30th Anniversary World Tour, their 2005 concert DVD. A staple of Rush's concerts was Neil Peart's drum solos, which included a basic framework of routines connected by sections of improvisation, making each performance unique. Each successive tour saw his solos become more advanced, with some routines dropped in favour of newer, more complex ones.
=== Initial training and conversion === Before Organized Reserve infantry divisions were ordered into active military service, they were reorganized on paper as "triangular" divisions under the 1940 tables of organization. The headquarters companies of the two infantry brigades were consolidated into the division's cavalry reconnaissance troop, and one infantry regiment was removed by inactivation. The field artillery brigade headquarters and headquarters battery became the headquarters. The headquarters battery of the division artillery, and its three field artillery regiments, were reorganized into four battalions. The engineer, medical, and quartermaster regiments were reorganized into battalions. In 1942, divisional quartermaster battalions were split into ordnance light maintenance companies and quartermaster companies. The division's headquarters and military police company, which had previously been a combined unit, was split.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.